The risk of systemic lupus erythematosus associated with vaccines: An international case-control study

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1559-1567

  Grimaldi Bensouda, Lamiae ^a   Le Guern, Veronique ^b   Kone Paut, Isabelle ^c   Aubrun, Elodie ^d   Fain, Olivier ^e,o   Ruel, Michel ^f   Machet, Laurent ^g,n   Viallard, Jean François ^h   Magy Bertrand, Nadine ⁱ   Daugas, Eric ^j   Rossignol, Michel ^k   Abenhaim, Lucien ^l   Costedoat Chalumeau, Nathalie ^m  

^a Bioinformatique et Chimie Moléculaire   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICÊTRE HOSPITAL   (France)

^d LA SER   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f Hopital Max Fourestier   (France)

^g INSERM   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^j BICHAT HOSPITAL   (France)

^k MCGILL UNIVERSITY   (Canada)

^l London School of Hygiene Tropical Medicine   (United Kingdom)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ UNIVERSITÉ DE TOURS   (France)

^o HÔPITAL JEAN VERDIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; VACCINE;

ADULT; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FRANCE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TELEPHONE INTERVIEW; VACCINATION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; FRANCE; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; QUEBEC; RETROSPECTIVE STUDIES; RISK FACTORS; VACCINATION; YOUNG ADULT;

EID: 84901634717     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38429     Document Type: Article

References (39)

1. Boumpas DT, Austin HA III, Fessler BJ, Balow JE, Klippel JH, Lockshin MD,. Systemic lupus erythematosus: emerging concepts. Part 1. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122: 940-50.
2. Boumpas DT, Fessler BJ, Austin HA III, Balow JE, Klippel JH, Lockshin MD,. Systemic lupus erythematosus: emerging concepts. Part 2. Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995; 123: 42-53.
3. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF,. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011; 63: 1182-9.
4. Stratta P, Mesiano P, Campo A, Grill A, Ferrero S, Santi S, et al. Life expectancy of women with lupus nephritis now approaches that of the general population. Int J Immunopathol Pharmacol 2009; 22: 1135-41.
5. Chen RT, Pless R, Destefano F,. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 2001; 16: 309-18.
6. Older SA, Battafarano DF, Enzenauer RJ, Krieg AM,. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum 1999; 29: 131-9.
7. Agmon-Levin N, Zafrir Y, Paz Z, Shilton T, Zandman-Goddard G, Shoenfeld Y,. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 2009; 18: 1192-7.
8. Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013; 32: 1301-7.
9. Millet A, Decaux O, Perlat A, Grosbois B, Jego P,. Systemic lupus erythematosus and vaccination. Eur J Intern Med 2009; 20: 236-41.
10. Touma Z, Gladman DD, Urowitz MB,. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr Opin Rheumatol 2013; 25: 164-70.
11. Mok CC, Ho LY, Fong LS, To CH,. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013; 72: 659-64.
12. Sturkenboom MC, Fautrel B, Rozenberg S, Begaud B, Roullet E, Heinzlef O,. Vaccinations against hepatitis B and lupus erythematosus. Pharmacoepidemiol Drug Saf 2000; 9: S195.
13. Geier DA, Geier MR,. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295-301.
14. Grimaldi-Bensouda L, Michel M, Aubrun E, Leighton P, Viallard JF, Adoue D, et al, for the PGRx Immune Thrombocytopenia Study Group. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood 2012; 120: 4938-44.
15. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
16. Grimaldi-Bensouda L, Aubrun E, Leighton P, Benichou J, Rossignol M, Abenhaim L, and the PGRx Study Group. Agreement between patients' self-report and medical records for vaccination: the PGRx database. Pharmacoepidemiol Drug Saf 2013; 22: 278-85.
17. Grimaldi-Bensouda L, Rossignol M, Aubrun E, Benichou J, Abenhaim L, and the PGRx Study Group. Agreement between patients' self-report and physicians' prescriptions on nonsteroidal anti-inflammatory drugs and other drugs used in musculoskeletal disorders: the international Pharmacoepidemiologic General Research eXtension database. Pharmacoepidemiol Drug Saf 2012; 21: 753-9.
18. Lahita RG,. Systemic lupus erythematosus. New York: Elsevier/Academic Press; 1992.
19. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al, for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16.
20. Direction de la Recherche, des Études, de l'Évaluation et des Statistiques (Drees). Les consultations et visites des médecins généralistes: un essai de typologie. Drees No. 315, June 2004. URL: http://onala.free.fr/drees315.pdf.
21. Grimaldi-Bensouda L, Alperovitch A, Besson G, Vial C, Cuisset JM, Papeix C, et al, for the GBS-PGRx Study Group. Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol 2011; 174: 326-35.
22. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41: 1828-34.
23. Elkayam O, Ablin J, Caspi D,. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 2007; 6: 312-4.
24. Aron-Maor A, Shoenfeld Y,. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 2001; 10: 237-40.
25. Del Porto F, Lagana B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis: safety and immunogenicity. Vaccine 2006; 24: 3217-23.
26. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 913-8.
27. Holvast B, Huckriede A, Kallenberg CG, Bijl M,. Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun Rev 2007; 6: 300-5.
28. Abu-Shakra M, Press J, Buskila D, Sukenik S,. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenicity issues. Autoimmun Rev 2007; 6: 543-6.
29. Wiesik-Szewczyk E, Romanowska M, Mielnik P, Chwalinska-Sadowska H, Brydak LB, Olesinska M, et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol 2010; 29: 605-13.
30. Lu CC, Wang YC, Lai JH, Lee TS, Lin HT, Chang DM,. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 2011; 29: 444-50.
31. Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfa E,. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007; 16: 350-4.
32. Ghaussy NO, Sibbitt WL Jr, Qualls CR,. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol 2001; 28: 2449-53.
33. Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ,. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case control study. Ann Rheum Dis 1998; 57: 451-5.
34. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS,. Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus. J Rheumatol 2001; 28: 2653-6.
35. Formica MK, Palmer JR, Rosenberg L, McAlindon TE,. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study. J Rheumatol 2003; 30: 1222-6.
36. Boeckler P, Cosnes A, Frances C, Hedelin G, Lipsker D,. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol 2009; 145: 1012-6.
37. Bengtsson AA, Rylander L, Hagmar L, Nived O, Sturfelt G,. Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford) 2002; 41: 563-71.
38. Wang J, Kay AB, Fletcher J, Formica MK, McAlindon TE,. Alcohol consumption is not protective for systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 345-8.
39. Ostensen M, Villiger PM, Forger F,. Interaction of pregnancy and autoimmune rheumatic disease. Autoimmun Rev 2012; 11: A437-46.